AFT Pharmaceuticals Limited announces the intravenous form of its patented pain relief medicine, Maxigesic IV, has now gained regulatory approval in both the UK and Ireland. Edge Pharmaceuticals, the licensee for the UK and Jed Pharma, the licensee in Ireland, are now gearing up to commence sales in the first quarter of the 2022 calendar year. The approvals bring the number of countries in which AFT Pharmaceuticals has obtained regulatory approval for Maxigesic IV to 27 from 21 countries at the end of March 2021. They also demonstrate the continuing progress AFT is making commercialising is intellectual property in the face of COVID-19 disruptions. More than 3.1million surgical procedures are performed in these markets each year. Maxigesic IV represents an effective non-opioid alternative for the management of mild to moderate pain for many of these cases.